Company intelligence / Profile preview

Tylomac-type biotech

Ownership: Private
Development stage: Other

Overview

Tylomac is a pharmaceutical company primarily focused on the development and commercialization of veterinary and human antibiotics. The company specializes in macrolide-class therapeutics, with its flagship products centered around tylosin-based formulations for livestock and companion animals. Tylomac's business model integrates research and development with large-scale manufacturing to address global needs in animal health and infectious disease management. Their portfolio includes a range of injectable, oral, and feed-additive solutions designed to treat respiratory and enteric infections.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Pharma

Beyond the preview

Go deeper on Tylomac-type biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tylomac-type biotech.

Explore the full profile